Published data on the association between paraoxonase1 (PON1) polymorphisms and coronary heart disease (CHD) have yielded controversial results. The objective of this study was to determine the possible relationship between the two human PON1 amino acid variants, the Leu55Met and the Gln192Arg polymorphism, and the risk of CHD in a community-dwelling cohort of European ancestry. PON1 genotypes of 152 women and 151 men out of 1,998 randomly selected individuals aged 44–75 years were determined by polymerase chain reaction-based restriction enzyme digestion. Study participants underwent cardiological examination including a structured clinical interview, resting ECG, exercise testing and echocardiography. The diagnosis of CHD was based on history and/or appropriate findings during cardiac examination. Evidence for CHD was found in 43 (14.2%) study participants. The Leu/Leu (LL), Leu/Met (LM) and Met/Met (MM) genotypes at position 55 were noted in 131 (43.2%), 128 (42.2%) and 44 (14.5%) subjects; the Gln/Gln (QQ), Gln/Arg (QR) and Arg/Arg (RR) genotypes at codon 192 occurred in 167 (55.1%), 118 (38.9%) and 18 (5.9%) individuals, respectively. Homozygosity for the 55L-allele was significantly associated with CHD (p = 0.02), while the Gln192Arg polymorphism had no effect (p = 0.16). Logistic regression analysis demonstrated age (odds ratio 1.06/year), smoking (odds ratio 2.86), HDL cholesterol (odds ratio 0.94/mg/dl) and the paraoxonase LL genotype (odds ratio 2.25) to be significant predictors of CHD. These data suggest that the paraoxonase LL genotype at position 55 may present a risk factor for CHD.

Keywords:
Paraoxonase, Genetics, Polymorphism, Coronary heart disease
1.
Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: Modification of low-density lipoprotein that increases its atherogenicity. N Engl J Med 1989;320:915–924.
2.
Parthasarathy S, Barnett J, Fong LJ: High density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275–283.
3.
Mackness MI, Mackness B, Durrington PN, Conelly PW, Hegele RA: Paraoxonase biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7:69–76.
4.
Mackness MI, Arrol S, Abbott CA, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129–135.
5.
Humbert R, Adler DA, Disteche CM, Hasset C, Omiecinski CJ, Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73–76.
6.
Watson AD, Berliner JA, Hama SY, La Du BM, Faull KF, Fogelman AM, Navab M: Protective effect of high density lipoprotein associated paraoxonase: Inhibition of the biological activity of minimally oxidised low density lipoprotein. J Clin Invest 1995;96:2882–2891.
7.
Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN: Effect of human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998;423:57–60.
8.
Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P: Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995;346:869–872.
9.
Serrato M, Marian J: A variant of human paraoxonase/arylesterase gene is a risk factor for coronary artery disease. J Clin Invest 1995;96:3005–3008.
10.
Sanghera DK, Saha N, Aston CE, Kamboh MI: Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997;17:1067–1073.
11.
Odawara M, Tachi Y, Yamashita K: Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:2257–2260.
12.
Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y: A 192-Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997;17:3565–3569.
13.
Pati N, Pati U: Paraoxonase gene polymorphism and coronary artery disease in Indian subjects. Int J Cardiol 1998;66:165–168.
14.
Pfohl M, Koch M, Enderle MD, Kuhn R, Fullhase J, Karsch KR, Haring HU: Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 1999;48:623–627.
15.
Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-Hashi Y, Yazaki Y: Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000;149:435–442.
16.
Osei-Hyiaman D, Hou L, Mengbai F, Zhiyin R, Zhiming Z, Kano K: Coronary artery disease risk in Chinese type 2 diabetics: Is there a role for paraoxonase 1 gene (Q192R) polymorphism? Eur J Endocrinol 2001;144:639–644.
17.
Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, Ehnholm C: The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996;98:883–885.
18.
Herrmann SM, Blanc H, Poirer O, Arveiler D, Luc G, Evans A: The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis 1996;126:299–303.
19.
Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, Hashimoto K: Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 1996;57:69–73.
20.
Rice GI, Ossei-Gerning N, Stickland MH, Grant PJ: The paraoxonase Gln-Arg 192 polymorphism in subjects with ischemic heart disease. Coron Artery Dis 1997;8:677–682.
21.
Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, Cheng NJ, Chen WJ, Chiang CW, Lee YS: The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 1998;141:259–264.
22.
Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, Cantini R, Campa PP, Ricci G, Arca M: The Gln-Arg 192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 1998;18:1611–1616.
23.
Karakaya A, Ibis S, Kural T, Köse SK, Karakaya AE: Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins. Chem Biol Interact 1999;118:193–200.
24.
Aubo C, Senti M, Marrugat J, Tomas M, Vila J, Sala J, Masia R: Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. Eur Heart J 2000;21:33–38.
25.
Cascorbi I, Laule M, Mrozikiewicz PM, Mrozikiewicz A, Andel C, Baumann G, Roots I, Stangl K: Mutations in the human paraoxonase 1 gene: Frequencies, allelic linkages, and association with coronary artery disease. Pharmacogenetics 1999;9:755–761.
26.
Gardemann A, Philipp M, Hess K, Katz N, Tillmanns H, Haberbosch W: The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 2000;152:421–431.
27.
Blatter-Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J: Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997;99:62–66.
28.
Sanghera DK, Saha N, Kamboh MI: The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of CHD in Asian Indians and Chinese. Atherosclerosis 1998;136:217–223.
29.
Hasselwander O, Savage DA, McMaster D, Loughrey CM, McNamee PT, Middleton D, Nicholls DP, Maxwell AP, Young IS: Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 1999;56:289–298.
30.
Salonen JT, Malin R, Tuomainen TP, Nyyssönen K, Lakka TA, Lehtimäki T: Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: Prospective nested case-control study. BMJ 1999;319:487–489.
31.
Schmidt R, Lechner H, Fazekas F, Niederkorn K, Reinhart B, Grieshofer P, Horner S, Offenbacher H, Koch M, Eber B, Schumacher M, Kapeller P, Freidl W, Dusek T: Assessment of cerebrovascular risk profiles in healthy persons: Definition of research goals and the Austrian Stroke Prevention Study. Neuroepidemiology 1994;13:308–313.
32.
Rose GA: The diagnosis of ischemic heart pain and intermittent claudication in field surveys. Bull WHO 1962;27:645–658.
33.
Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S: The electrocardiogram in population studies: A classification system. Circulation 1960;21:1160–1175.
34.
ACC/AHA Task Force on Practice Guidelines: Guidelines for exercise testing. J Am Coll Cardiol 1997;30:260–315.
35.
Edwards WD, Tajik AJ, Seward JB: Standardized nomenclature and anatomic basis for regional tomographic analysis of the heart. Mayo Clin Proc 1981;56:479–497.
36.
Schmidt H, Schmidt R, Niederkorn K, Gradert A, Schumacher M, Watzinger N, Hartung HP, Kostner GM: Paraoxonase PON1 polymorphism Leu-Met54 is associated with carotid atherosclerosis: Results of the Austrian Stroke Prevention Study. Stroke 1998;29:2043–2048.
37.
Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, Navab M, Shih D, Fonarow GC: Paraoxonase and coronary heart disease. Curr Opin Lipidol 1998;9:319–324.
38.
Mackness B, Hunt R, Durrington PN, Mackness MI: Increased immunolocalisation of paraoxonase, clusterin and apolipoprotein A1 in the human artery wall with progress of atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:1233–1238.
39.
Mackness MI, Mackness B, Arrol S, Wood G, Bhatnagar D, Durrington PN: Presence of paraoxonase in human interstitial fluid. FEBS Lett 1997;416:377–380.
40.
Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN: Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997;112:265–268.
41.
Mackness B, Mackness MI, Durrington PN, Arrol S, Evans AE, McMaster D, Ferrieres J, Ruidavets JB, Williams NR, Howard AN: Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest 2000;30:4–10.
42.
Jarvik GP, Rozek LS, Brophy VH, Hatsukmai TS, Richter RJ, Schellenberg GD, Furlong CE: Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 (192) or PON1 (55) genotype. Arterioscler Thromb Vasc Biol 2000;20:2441–2447.
43.
Rose G, Hamilton PJS, Keen H, Reid DD, McCartney P, Jarrett RJ: Myocardial ischemia, risk factors and death from coronary heart disease. Lancet 1977;i:105–109.
44.
Leviev I, James RW: Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000;20:516–521.
45.
Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN: The human serum paraoxonase/aryltransferase gene (PON1) is one member of a multigene family. Genomics 1996;33:498–507.
46.
Sanghera DK, Aston CE, Saha N, Kamboh MI: DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with risk of coronary heart disease. Am J Hum Genet 1998;62:36–44.
47.
Leus FR, Zwart M, Kastelein JJ, Voorbij HA: PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 2001;154:641–649.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.